Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/15320
Title: Cost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care System
Authors: Ko, YJ
Coyle, K
Saluja, R
Shah, K
Lien, K
Lam, H
Chan, KKW
Keywords: Chemotherapy;Cost-Effectiveness Analysis;Economic Evaluation;Gemcitabine;Advanced pancreatic cancer;Bayesian network meta-analysis
Issue Date: 2017
Citation: Value in Health, 2017, 20 (4), pp. 586 - 592
Abstract: © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Objectives To assess the cost-effectiveness of gemcitabine (G), G + 5-fluorouracil, G + capecitabine, G + cisplatin, G + oxaliplatin, G + erlotinib, G + nab-paclitaxel (GnP), and FOLFIRINOX in the treatment of advanced pancreatic cancer from a Canadian public health payer's perspective, using data from a recently published Bayesian network meta-analysis. Methods Analysis was conducted through a three-state Markov model and used data on the progression of disease with treatment from the gemcitabine arms of randomized controlled trials combined with estimates from the network meta-analysis for the newer regimens. Estimates of health care costs were obtained from local providers, and utilities were derived from the literature. The model estimates the effect of treatment regimens on costs and quality-adjusted life-years (QALYs) discounted at 5% per annum. Results At a willingness-to-pay (WTP) threshold of greater than $30,666 per QALY, FOLFIRINOX would be the most optimal regimen. For a WTP threshold of $50,000 per QALY, the probability that FOLFIRINOX would be optimal was 57.8%. There was no price reduction for nab-paclitaxel when GnP was optimal. Conclusions From a Canadian public health payer's perspective at the present time and drug prices, FOLFIRINOX is the optimal regimen on the basis of the cost-effectiveness criterion. GnP is not cost-effective regardless of the WTP threshold.
URI: http://bura.brunel.ac.uk/handle/2438/15320
DOI: http://dx.doi.org/10.1016/j.jval.2016.11.002
ISSN: 1098-3015
1524-4733
Appears in Collections:Dept of Clinical Sciences Embargoed Research Papers

Files in This Item:
File Description SizeFormat 
Fulltext.pdf482.87 kBAdobe PDFView/Open    Request a copy


Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.